Online Lawyer Source

The FDA approved Fosamax in 1995 for the treatment of bone related conditions, specifically for osteoporosis in men and post-menopausal women as well as for Paget’s Disease and cancers that had metastasized to the bone.  When first introduced, Fosamax was thought as a savoir for the loss of bone mass.  Increase in bone mass usually started to increase in the span of three months after taking the prescription and a whopping 96% of patients taking Fosamax increased or maintained bone mass.  However, a link between Fosamax and a bone deteriorating condition called Osteonecrosis, literally translated meaning “dead bone” was established by experts at the Long Island Jewish Medical Center in 2004.  According to the study, Fosamax is believed to actually create lesions in the jawbone there by making it more fragile and susceptible to infection.  These risks are exponentially increased if any of the following have occurred:

• Taken bisphosphonates such as Fosamax, especially IV formulations. Concurrent use of steroids seems to increase the risk.
• A previous history of cancer (especially metastatic disease to the bone), osteoporosis, or Paget's disease
• A history of invasive dental procedures such as tooth extraction, dental implants, or other oral surgeries.

Osteonecrosis is a serious condition that requires immediate medical attention.  If you or a loved on has taken Fosamax in the past, contacting a dental profession will help determine if you are at risk for developing Osteonecrosis.  If you are currently suffering from Osteonecrosis, you don’t have to suffer in vain, contact an attorney today.

Proud Members of the Better Business Bureau